Katherine Lewin

The cost-ef­fec­tive­ness watch­dog ICER found that Ver­tex’s fu­ture non-opi­oid treat­ment for acute pain could be cost-sav­ing, but on­ly at a low price, ac­cord­ing to a

Bio­con Bi­o­log­ics scored an FDA ap­proval for its Ste­lara biosim­i­lar, mar­ket­ed as Yesin­tek, the com­pa­ny an­nounced Mon­day. Bio­con en­tered in­to a … Sign up to

Ole­ma On­col­o­gy is again team­ing up with No­var­tis, with the com­pa­nies part­ner­ing on a new clin­i­cal tri­al col­lab­o­ra­tion and sup­ply agree­ment for an in­ves­ti­ga­tion­al breast

Ax­some Ther­a­peu­tics’ nar­colep­sy drug AXS-12 hit the pri­ma­ry end­point in its Phase 3 EN­CORE tri­al, show­ing a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in the fre­quen­cy of cat­a­plexy

Mer­ck is stop­ping a Phase 3 tri­al of its pul­monary ar­te­r­i­al hy­per­ten­sion treat­ment Win­re­vair al­most a year ear­ly fol­low­ing pos­i­tive in­ter­im da­ta, the com­pa­ny …